The options for treatment of diffuse large B-cell lymphoma (DLBCL) have expanded in recent years, particularly with the emergence of bispecific antibodies. Today's activity will focus on enhancing knowledge and competence in managing DLBCL at first relapse. The agenda includes discussions on treatment goals, factors influencing eligibility for different therapies, patient experiences, personalized treatment selection, and the emerging role of bispecific antibodies. You will learn about the patient perspective, communication strategies for shared decision-making, and considerations for integrating new therapies like bispecific antibodies. Interactive case-based discussions will highlight physician and patient perspectives in selecting therapy for patients who are not candidates for transplant or chimeric antigen receptor (CAR) T-cell therapy. The session will end with essential insights from the expert faculty, summarizing today's DLBCL management journey.